U.S. markets open in 2 hours 53 minutes

CBD Unlimited, Inc. (EDXC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1898-0.0002 (-0.11%)
At close: 3:56PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1900
Open0.1909
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1740 - 0.2000
52 Week Range0.0310 - 0.2849
Volume666,321
Avg. Volume1,583,554
Market Cap31.962M
Beta (5Y Monthly)2.83
PE Ratio (TTM)N/A
EPS (TTM)-0.0050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Endexx Files Form 10 Registration Statement for SEC Review
    GlobeNewswire

    Endexx Files Form 10 Registration Statement for SEC Review

    CAVE CREEK, AZ, March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Endexx Corporation (OTC: EDXC), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products, today announced that it has publicly filed its Registration Statement on Form 10 with the Securities and Exchange Commission (SEC). This is a voluntary filing that is subject to SEC review. If the Registration Statement becomes effective, it would designate Endexx as an SEC reporting company and register the class of its shares of common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Additionally, if the Registration Statement become effective, investors, who purchased or purchase shares of the Company’s common stock through private placements, would be permitted to resell their shares into the public markets pursuant to the exemption from registration under Rule 144 of the Securities Act of 1933, as amended, subject to compliance with the Rule’s provisions. Endexx currently publishes quarterly and annual reports, which include its financial statements, and is in compliance with the OTC Markets Group’s Alternative Reporting Standards. If the Registration Statement becomes effective, Endexx would file these reports and financial statements in the form of 10-Qs and 10-Ks with the SEC, along with Current Reports on Form 8-K, in addition to complying with its other obligations under the Exchange Act. See Filing: https://sec.report/Document/0001493152-21-005346/ About Endexx Corporation Endexx Corporation, through its operating subsidiary CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab-work to provide accuracy in dosage and delivery of optimal absorption per serving. Safe Harbor Notice This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the OTC Markets Group’s and the Company’s Form 10 filed with the SEC. The company undertakes no obligation to update any forward-looking statements. Contact: For further investor and media information, contact: Endexx Corporation Todd Davis Chairman & CEO Endexx@endexx.com 480-595-6900

  • Endexx Corporation Announces Participation in the Benzinga Virtual Cannabis Capital Conference
    GlobeNewswire

    Endexx Corporation Announces Participation in the Benzinga Virtual Cannabis Capital Conference

    Cave Creek, AZ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Endexx Corporation (OTC PINK:EDXC) will be presenting at the Benzinga Cannabis Capital Conference taking place on February 25-26, 2021 at 1:50 pm EST/11:50 am MST. We invite our shareholders to sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration About Benzinga Cannabis Capital Conference Benzinga's virtual Cannabis Capital Conference is guaranteed to offer participants all the benefits of an immersive and robust in-person conference from any remote location. The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space. Don't miss this opportunity to connect with THE cannabis movers and shakers from across the globe. For more information and/or to register for the conference please visit: https://events.benzinga.com/ccc-free-registration We look forward to seeing you there. About Endexx Corporation Endexx Corporation, through its operating division CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work to provide accuracy in dosage and delivery of optimal absorption per serving. Endexx Corporation Todd Davis 4805956900 endexx@endexx.com www.endexx.com

  • GlobeNewswire

    Endexx Announces Fiscal Year-End Financial Results; Year Over Year Revenues Grow 79 Percent

    Endexx launches 2021 with Accelerated Contract Revenue CAVE CREEK, AZ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Endexx Corporation (OTC: EDXC), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products, today announced its fiscal 2020 annual report. Endexx is pleased to report record revenue $1.97 million with growth of 78 percent year over year. The company generated its first gross profit on an annual basis in fiscal 2020. 2020 Milestones and Highlights: Joint Venture • Endexx signs contract with DJ Khaled to launch new CBD Brand and Category International Expansion · Cleared to Distribute CBD Products in Guam. · Jamaica’s CLA grants provisional licenses for Retail and Cultivation. Increased Distribution Reach · Endexx secured a Master Distribution contract with the leading distributor in North America. · Distribution contract provides access to over 1,000,000 stores in the United States. Product Innovation · Endexx launches new “Value Line” in December to reach wider audience with more accessible price point options. · Endexx creates five unique products to be sold at counter as a POP Impulse buy. · Endexx rebranded its Premium line. Acquisitions • Endexx acquired Kush Inc. (Kushwear Brands) • Endexx acquired CBD Life Brands (Nero Water) • Endexx acquired Retail Pro Associates (Ronald Cotting and Stephen Herron) “Even in light of the most challenging year ever for the company, the industry and the market, Endexx was able to survive and thrive in fiscal 2020,” stated CEO Todd Davis. Davis added, “Endexx is positioned to accelerate top line revenue growth exponentially in 2021. Covid 19 allowed us to rethink and reposition our company and its product lines to better meet the needs of its customers. We built new price point sensitive products and point of purchase impulse buy lines providing support to our sales and distribution partners. We secured the most dominant and widespread Master Distributor in the US. We then secured one of the single greatest influencers in the Music and Entertainment industry domestically and globally to both represent our products and collaborate to design a new category and market in the CBD Industry. Mr. DJ Khaled has partnered with Endexx to deliver the most exciting new wellness products in the Industry in 2021 and beyond. Adversity has brought our collective team together and has driven our focus on success and execution of our mission for years to come,” Davis concluded. www.endexx.com & www.cbdunlimited.com About Endexx Corporation Endexx Corporation, through its operating division CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work to provide accuracy in dosage and delivery of optimal absorption per serving. Safe Harbor Notice This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements. Contact: For further investor and media information, contact: Endexx Corporation Todd Davis Chairman & CEO Endexx@endexx.com 480-595-6900